Aim: Since fetal therapy has been newly developed, objective evaluation of adverse events (AE), all harmful events that are not always related to the procedures, has not yet been adequately reported. We established new terminology and tried to re-evaluate it based on the Japanese prospective thoraco-amniotic shunting (TAS) study. Methods: From the literature, all complications that occurred with all fetal therapies were identified as a basis for developing the terminology. Grading was set from 0 to 5. Grade 3 was defined as the need for invasive treatment, such as surgery. Grade 4 was defined as life-threatening, and Grade 5 was defined as death of the mother or fetus. Then, one series of TAS that we had already reported was re-evaluated, including 24 cases with 37 procedures and 200 opportunities those could be evaluated AE after procedures. Results: Grade 4 preterm rupture of the membranes was reported in only 1 of 24 cases. Catheter displacement was reported in 7, 2 and 11 cases, of Grades 1, 2 and 3, respectively. It was found that the double-basket catheter had some association with catheter displacement, but it was clear that there were no life-threatening AE. Conclusion: Newly developed AE criteria are now available for fetal therapy. They will contribute to the objective evaluation of AE of new fetal therapies in the future.
Introduction
Fetal therapy has recently been widely performed world-wide. Laser surgery for severe twin-to-twin transfusion 1,2 and thoraco-amniotic shunting (TAS)
for severe pleural-effusion with hydrops fetalis are relatively commonly performed in Japan. 3 Since fetal therapy has been newly developed, objective evaluation of adverse events (AE) has not yet been adequately reported. In order to establish fetal therapy as a common medical option, we should report not only its effectiveness, but also its AE. In the area of cancer therapy, Common Terminology Criteria for Adverse Events (CTCAE) 4, 5 are widely used for evaluating AE objectively, based on the guidelines of the International Conference on 6 AE are defined as all undesired events, laboratory data, symptoms, and diseases that are not always related to the preceding procedures and therapy. These descriptive terminologies are used to scientifically evaluate therapies based on their effectiveness and AE. In the field of fetal therapies, many articles have reported not AE, but 'complications', which have no clear definition, and there might not be any differentiation between the two terminologies. Furthermore, the standard criteria for AE have not yet been established. In this study, the complications of fetal therapies from the major prospective studies, such as randomized clinical trials (RCT) were reviewed. Then, the goal was to establish objective common terminology criteria for the AE of fetal therapy, and then to evaluate whether such newly developed criteria could be used for one prospective study involving one model, such as TAS using a double-basket catheter. 3 This methodology might be a new proposal for evaluating not only the effectiveness, but also the AE of fetal therapies, in order to establish fetal therapies as a standard medical option.
Methods
Articles of RCT or systematic prospective studies of fetal therapies that objectively evaluated complications in detail were identified. From these reviews, all complications were gathered as a basis for the terminology for AE that could possibly happen for all fetal therapies. First, CTCAE for fetal therapy were established with reference to CTCAE ver. 4 for cancer-related medicine, using a grading from 0 to 5. Grade 0 was defined as free from AE. Grade 1 was defined as some AE requiring no treatment. Grade 2 was defined as AE requiring usual treatment, such as medication. Grade 3 was defined as AE requiring invasive treatment such as surgery, not usual drugs. Grade 4 was defined as lifethreatening AE and Grade 5 was defined as AE resulting in death of the mother or fetus (Fig. 1 ). Compared to CTCAE ver. 4, they were specific because they involved pregnant women, the fetus or both. Not only complications, but also all severe AE of fetal therapy reported previously [1] [2] [3] [7] [8] [9] [10] [11] [12] were reviewed, though almost all were collected from retrospective reports and seemed to be systematic.
Second, one series of TAS that we previously reported (University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN00001095)) was reviewed. 3 Using this prospective multicenter series, all AE were categorized as Grade 0-5 using our CTCAE for fetal therapy as a retrospective cohort. In this series, there were 24 cases with 37 procedures and 200 opportunities for evaluating AE after procedures.
Results
Randomized clinical trials and prospective systematic articles of laser surgery for twin-twin transfusion syndrome, 1,2 TAS for severe hydrops fetalis, 3 fetal blood transfusion, 10 fetal open surgery for myelomeningocele, 11 maternal medication for fetal arrhythmia, 12 and so on were reviewed. The terminology of complications was collected from each article. In the reviews, the complications of fetuses, placenta and uterus, and mother were gathered. Terminology such as fetal death, preterm deliveries included preterm rupture of the membranes (PROM), bleeding by centesis of the uterus, fetal and maternal organ injuries, drug side effects, and hypertensive disorder, Figure 1 Grade classification of adverse events of fetal therapy. (Table 1) . Using these criteria for AE, the AE scores of a prospective Japanese series of TAS for 24 cases were analyzed, and they are shown in tables as a retrospective cohort (Tables 2 and 3 ). Fetal life-threatening PROM was reported in only 1 of 24 cases. The management of threatened preterm delivery of Grades 1, 2 and 3 was reported 43, 110 and 9 times, respectively, over all opportunities. Catheter displacement was reported in 7, 2 and 11 cases as Grades 1, 2 and 3, respectively. This analysis showed that the doublebasket catheter had some association with catheter displacement and needed to be removed from neonates and the uterus after deliveries, but it is clear that there were no life-threatening AE. For the mothers, there were no life-threatening events, but three mirror syndrome cases that required intensive medical treatment were reported. No uterine infections and placental abruptions were reported. Only one chorioamniotic membrane separation was reported.
Discussion
Recent prospective studies, such as those of interventions by new operations or new drugs, are being considered more objectively and clearly, especially with respect to patient rights. From this perspective, it is clear that we should take note of all AE during prospective studies. Currently, some articles have noted complications, not all AE, but selected complications subjectively determined by the authors or researchers to have some relationship with the medical treatment. With such an approach, some events would not be noted, even not necessarily willingly. The ICH currently recommends noting all AE, irrespective of their relationship to the medical treatment, 6 and some cancer associations started to establish a new system of reporting AE, such as, in the USA, the National Cancer Institute Cancer Therapy Evaluation Program. 13 Fetal therapy is a new medical attempt to rescue the fetuses that we have not been able to save with neonatal management alone over the last 30 years. However, scientifically, there have been few large RCT, and almost all articles do not note all complications or all AE. So our proposal for using common terminology for the AE of fetal therapy is a new attempt to establish such therapies as a common medical option. Researchers and doctors do not need to consider the relationships and causes of events, but they should automatically record the scores. This may result in more objective accumulation of information for new treatments, not only efficacy, but also real complications.
Especially for the establishment of AE terminology for fetal therapy, major journals and some guidelines (NICE, 7, 8 etc.) were reviewed, and almost all AE were collected. The focus must be on the fetus, placenta and uterine cavity, and mother. The most important words are 'preterm delivery', because of uterine centesis causing preterm PROM and uterine contractions. We also need to consider the levels of the neonatal intensive care units of each country to determine the grades (0-5) of neonatal prognosis.
The present retrospective cohort study developed a more objective evaluation using a sample involving TAS we previously reported. 3 Using the new added criteria for AE, new therapies can be evaluated objectively. Grades 4-5 events, which are life-threatening for both the fetus and mother, appear rarely after TAS. This seems to be caused by good tube characteristics (double-basket catheter diameter of 1.47 mm), 3 which is the thinnest diameter in the world (compared to the double pig tail catheter from Rocket of London Ltd, Watford, UK which was 2.1 mm) and showed minimal invasiveness. However, it became evident that this tube has dislocation events, and that we should know the two aspects of good efficacy and AE of newly developed devices for treatment.
In conclusion, the present study succeeded in providing new terminology for evaluating AE in fetal therapies. We can now use the new criteria when performing fetal therapies in prospective studies. This may also clarify how to compare the safety of different studies of fetal therapies, techniques, institutes, periods and physicians for the same disease objectively. By describing the AE systematically, this innovation for medical research would contribute to providing reliable medicine to the patients.
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